Pilot Study of NovoTTF-100A for Recurrent Atypical and Anaplastic Meningioma
A study for patients with progressive meningioma using study device NovoTTF-100A
Sponsor: Memorial Sloan Kettering Cancer Center
Enrolling: Male and Female Patients
IRB Number: AAAO4805
U.S. Govt. ID: NCT01892397
Contact: Teri Kreisl: 212-342-0571 / tnk2109@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out what effects, good or bad, the experimental device, NovoTTF-100A has on patients with meningioma. This study is being done because currently there are no proveneffective medical treatments for a progressive meningioma that has failed surgery and/or radiation. The NovoTTF-100A System is a portable medical device. It delivers electric fields called TTFields to the brain using transducer arrays which are sticky pads placed on the scalp. TTFields are intended to kill cancer cells..
This study is closed
Teri Kreisl, MD
Do You Qualify?
Have you been diagnosed with meningioma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Teri Kreisl